Patient deaths halt study of new approach to treating cancer (experimental drug JCAR015/others) Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Wednesday, November 23, 2016

Patient deaths halt study of new approach to treating cancer (experimental drug JCAR015/others)



Patient deaths halt study of new approach to treating cancer


 With the two new deaths, Juno faces tough questions about the safety of its therapy, called JCAR015. And the FDA will likely come under fire for allowing the company to get back to work just days after the first clinical hold.
 JUNO: https://www.junotherapeutics.com/pipeline/clinical/

 MUC16

JCAR020NCT02498912A Phase I Clinical Trial of Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer 

clinicaltrials.gov:


Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2016 by Memorial Sloan Kettering Cancer Center
Sponsor:
Collaborators:
Stanford University
Juno Therapeutics, Inc.
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

0 comments :

Post a Comment

Your comments?